The China Securities Regulatory Commission (CSRC) disclosed on March 6 that six companies have obtained filing approvals for their initial public offerings (IPOs) in Hong Kong. The approved firms include Kefu Medical Technology Co., Ltd., Shenghong Technology (Huizhou) Co., Ltd., Shenzhen Medcaptain Medical Technology Co., Ltd., Beijing Deep演Intelligence Technology Co., Ltd., Puyuan Jingdian Technology Co., Ltd., and Shenzhen LDROBO Robotics Co., Ltd.

1. Kefu Medical Technology Co., Ltd. Kefu Medical was listed on the Shenzhen Stock Exchange's ChiNext board on October 25, 2021, with stock code 301087. Its IPO price was 93.09 yuan per share, raising a total of 3.724 billion yuan, with net proceeds of 3.527 billion yuan. According to its Hong Kong IPO prospectus, the company is a leading comprehensive provider of home medical devices in China, ranking second in domestic revenue among home medical device enterprises in 2024. Its brands include Kefu, Beibeijia, and Jian'er Hearing. The company submitted its application to list H-shares on the Hong Kong Stock Exchange's main board on August 29, 2025, which lapsed in late February 2026 upon expiry of the application validity period. However, the company continues to advance its Hong Kong IPO process and received the CSRC's overseas listing filing notice on March 6, 2026. According to its Q3 2025 report, the company reported revenue of 2.398 billion yuan and non-GAAP net profit of 222 million yuan for the first nine months of 2025.

2. Shenghong Technology (Huizhou) Co., Ltd. Shenghong Technology was listed on the Shenzhen Stock Exchange's ChiNext board on June 11, 2015, with stock code 300476. Its IPO price was 15.73 yuan per share, raising a total of 577 million yuan, with net proceeds of 533 million yuan. Its Hong Kong IPO prospectus states that the company is a global leading supplier of PCBs for artificial intelligence and high-performance computing, ranking first globally in AI and high-performance computing PCB revenue in Q1 2025. Core products include AI computing cards, AI servers, high-end HDI boards, and PCBs for new energy vehicles. The company submitted its Hong Kong IPO application on August 20, 2025, which lapsed in February 2026. It refiled an updated application on February 24, 2026, and received the CSRC's overseas listing filing notice on March 6, 2026. According to its Q3 2025 report, the company achieved revenue of 14.117 billion yuan and non-GAAP net profit of 3.248 billion yuan for the first nine months of 2025.

3. Shenzhen Medcaptain Medical Technology Co., Ltd. Medcaptain Medical was founded in 2011 and has completed multiple rounds of equity financing, raising approximately 2.259 billion yuan in total. It has attracted well-known institutional shareholders including Shenzhen Capital Group, Hillhouse Capital, and Lilly Asia Ventures, with a post-money valuation reaching 8.2 billion yuan after its Series E financing in 2023. According to its Hong Kong IPO prospectus, the company is a global medical solutions provider with core businesses covering life support, minimally invasive intervention, and in-vitro diagnostics. It submitted its Hong Kong IPO application on September 11, 2025, and received the CSRC's overseas listing filing notice on March 6, 2026. For the first half of 2025, the company reported revenue of 787 million yuan, profit of 40.968 million yuan, and a gross margin of 52.9%.

4. Beijing Deep演Intelligence Technology Co., Ltd. Deep演Intelligence was founded in April 2009 and has completed multiple rounds of equity financing, raising over 546 million yuan. Institutional shareholders include China Mobile Fund and Shenzhen Capital Group. The company previously applied for listing on the Shenzhen Stock Exchange's ChiNext board in June 2022 but withdrew the application in June 2024. According to its Hong Kong IPO prospectus, it is a leading decision-making AI technology company in China, ranking first in China's marketing and sales decision-making AI application market by 2024 revenue (2.6% market share) and fourth in China's overall decision-making AI application market (1.6% market share). The company first submitted its Hong Kong IPO application on May 28, 2025, which lapsed in November 2025. It refiled on December 1, 2025, and received the CSRC's overseas listing filing notice on March 6, 2026. For the first half of 2025, the company reported revenue of 277 million yuan and net profit of 3.639 million yuan.

5. Puyuan Jingdian Technology Co., Ltd. Puyuan Jingdian was listed on the Shanghai Stock Exchange's STAR Market on April 7, 2022, with stock code 688337. Its IPO price was 60.88 yuan per share, raising a total of 1.826 billion yuan, with net proceeds of approximately 1.749 billion yuan. According to its Hong Kong IPO prospectus, the company is China's largest electronic measurement instrument supplier, ranking eighth globally by 2024 revenue (1.1% market share). Its core brand is RIGOL. The company submitted its Hong Kong IPO application on September 29, 2025, and received the CSRC's overseas listing filing notice on March 6, 2026. According to its Q3 2025 report, the company achieved revenue of 597 million yuan and net profit attributable to shareholders of 2.2551 million yuan for the first nine months of 2025. Its 2025 preliminary results show full-year revenue of 900 million yuan, net profit attributable to shareholders of 85.205 million yuan, and non-GAAP net profit of 37.5998 million yuan.

6. Shenzhen LDROBO Robotics Co., Ltd. LDROBO Robotics was founded in November 2017 and has completed multiple rounds of equity financing, raising over 468 million yuan. Institutional shareholders include Shenzhen HTI Group, Yuanjing Capital, China Unicom & CICC Fund, Huawei Venture Capital, Source Code Capital, and New Hope Group. According to its Hong Kong IPO prospectus, the company is a global leading full-stack intelligent robotics company based on perception intelligence. Core businesses cover visual perception products and integrated intelligent robots, featuring products such as Mini DTOF radar sensors and AI-powered lawn mowing robots. The company first submitted its Hong Kong IPO application on May 30, 2025, which lapsed in late November 2025. It refiled on December 1, 2025, and received the CSRC's overseas listing filing notice on March 6, 2026. For the first half of 2025, the company reported revenue of 386 million yuan, a 97% year-on-year increase, with a net loss of 13.78 million yuan.